GeneDx Holdings (WGS) Cash from Financing Activities (2020 - 2026)
GeneDx Holdings has reported Cash from Financing Activities over the past 7 years, most recently at $38.6 million for Q1 2026.
- Quarterly Cash from Financing Activities rose 181.31% to $38.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $72.9 million through Mar 2026, up 25.0% year-over-year, with the annual reading at $48.0 million for FY2025, 8.75% up from the prior year.
- Cash from Financing Activities was $38.6 million for Q1 2026 at GeneDx Holdings, up from $23.2 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $198.1 million in Q2 2022 and troughed at -$911000.0 in Q3 2023.
- The 5-year median for Cash from Financing Activities is $10.8 million (2025), against an average of $30.3 million.
- Year-over-year, Cash from Financing Activities surged 83011.25% in 2023 and then tumbled 105.29% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at $65000.0 in 2022, then surged by 72366.15% to $47.1 million in 2023, then plummeted by 34.14% to $31.0 million in 2024, then decreased by 25.24% to $23.2 million in 2025, then skyrocketed by 66.39% to $38.6 million in 2026.
- Per Business Quant, the three most recent readings for WGS's Cash from Financing Activities are $38.6 million (Q1 2026), $23.2 million (Q4 2025), and $10.8 million (Q3 2025).